BioMarin hosted a conference call Conference call to discuss results of the GALNS Phase 3 Trial was held on November 5 at 8:30 am and has a replay available from 10:30 am on November 5 through November 12. Webcast Link
BioMarin upgraded to Buy from Neutral at Goldman Goldman upgraded BioMarin to Buy based on increased confidence in BMN-111 for achondroplasia with expected proof-of-concept data in Q2 2015. The firm now sees a greater than 50% probability of success and peak sales of $900M. Price target raised to $104 from $78.